RxBlog

Sponsor Media

RxBlog Resources

RxBlog Blogroll

  • Pfizer
    Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment.
  • Schering-Plough
    We aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.
  • Wyeth
    Wyeth pharmaceutical company brings health care products, medicines and vaccines that aim to improve lives and deliver value to customers.
  • Novartis
    Novartis is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and to enhance the quality of life.
  • GlaxoSmithKline
    Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
  • AstraZeneca
    One of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas.
  • Merck
    A global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Sponsor Links


My Online Status

Sponsor Video

« November 2006 | Main | April 2007 »

The U.S. healthcare system is dysfunctional, one that rewards the wrong things and doesn't create value for the consumer.

The United States has a system with the wrong kind of competition, on the wrong things. Instead, we have a zero-sum competition to restrict services, assemble bargaining power, shift the cost to others, or grab more of the revenue versus other actors in the system.

Zero-sum competition does not create value; it can actually destroy value by adding administrative costs and leads to structures involving health plans and providers and other actors, which are misaligned with patient value. In a world of zero-sum competition, for example, providers will consolidate into provider groups to gain clout against insurers. But, as we point out in our book, the provider group doesn't create any value. Value is not created by breadth of services but excellence in particular medical conditions.

» Search Risk-Specific Tags: prescription drug benefit - value-driven healthcare - healthcare reform
» HBS Working Knowledge

IMPACT 2007, Biotech Study Finds Challenges to Biotechnology Industry

BayBio, a biotechnology industry organization, published its study BayBio: IMPACT 2007.

What does Northern California know about the state of biotechnology? That region alone is home to 1/3 of the U.S.'s biotech companies, and has 30 years of involvement in the industry.

In the report, BayBio cites numerous existing challenges that threaten the prosperity of the biotech industry despite tremendous advances and achievements.

Some key facts and statistics of the report are:

  • 393 marketed products, 400 products in Phase II and Phase III clinical trials
  • 90,000 employees, accounting for more than $6 billion in payroll in 2006
  • Estimated new jobs created in the past 12 months: 6,000
  • 900 biotech companies in Northern California
  • Collective market capitalization: $150 billion
  • Average time for FDA approval of a new drug: 14 years
  • Average cost for development of a new drug: $800 million

BayBio: IMPACT 2007